VIVITRA - Trastuzumab Lyophilized Powder

A drug called trastuzumab is used to treat breast cancer that has the HER2 gene mutation as well as several other malignancies that also have this mutation. This monoclonal antibody targets the HER2 protein, which is overexpressed in malignancies that test positive for the protein. Trastuzumab suppresses the growth of cancer cells by interacting with HER2 receptors, which also alerts the immune system to attack the cancer cells. Before being administered as an intravenous infusion, the medicine must be reconstituted and diluted from its lyophilized powder form. The use of trastuzumab is a crucial part of targeted therapy in the management of breast cancer since it has dramatically improved treatment results for patients with HER2-positive tumours. To successfully control any adverse effects during therapy, routine monitoring is crucial.